Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

• Status: Completed
• Trial end date: 2019-09-19
• Target enrollment: 0
• Participant gender: All

Summary

The current project applies an integrative three-prong approach to investigate the potential of the dopamine D2 receptor (DRD2) agonist bromocriptine to: 1) increase homeostatic satiation signaling, 2) alter neural circuitry to reduce hedonically motivated food intake, and 3) examines a genetic predisposition that may markedly impact the effectiveness of this medication in those at high risk for T2DM.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of North Carolina, Chapel Hill
• Collaborator: American Diabetes Association
• Treatments: Bromocriptine

Criteria

Inclusion Criteria:

• Baseline BMI between 25 and 35

Exclusion Criteria:

• Individuals with current fMRI contraindications (e.g., metal implants, braces)

• Probable current Axis I psychopathology (e.g., major depression disorder, panic disorder, generalized anxiety disorder, bipolar disorder)

• Habitual use of cigarettes or illicit drugs

• Pregnancy or breastfeeding

• Diagnosis of serious medical problems (e.g., diabetes, cardiovascular disease, stroke)

• Current weight loss dieting and/or weight fluctuations great than 10 lbs in the previous 6 weeks

• Do not consume dairy

• Allergy to bromocriptine, dairy, and nuts